IGC Pharma Begins Patient Enrollment for Phase 2 Alzheimer’s Agitation Trial at Neurostudies IGC Pharma has commenced patient enrollment at Neurostudies, Inc. in Port Charlotte, Florida, for its Phase 2…
A leader in Personalized Therapy Decision Support and Precision Drug Development, Cellworks, has announced the opening of a CLIA-certified computational laboratory in Franklin, Tennessee. Administered by the Centers for Medicare…
Be Biopharma Announces FDA Clearance for BE-101 IND Application in Hemophilia B Be Biopharma, Inc. (“Be Bio”), a pioneer in Engineered B Cell Medicines (BCMs), has announced the U.S. Food…
A clinical-stage biotechnology company developing biologics to enhance regulatory T cell (Treg) function, Coya Therapeutics, has announced that MSCI has included its shares in the MSCI USA Micro Cap Index…
Integrated Biosciences, a biotechnology company leveraging synthetic biology and machine learning to create next-generation therapeutics for age-related diseases, announced its collaboration with Illumina Ventures Labs. This partnership aims to integrate…
The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Sarclisa (isatuximab) for Priority Review. The application is for the investigational use of Sarclisa…
A Journey from Curiosity About Life on Earth to Transformative Therapies at Novartis When I was young, my fascination with science began with the natural world and animals. A BBC…
High-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which previously met the primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) over docetaxel in patients…
Roche announced today that James Sabry (born 1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with the company. James Sabry joined Genentech in 2010 as Head…
A biopharmaceutical company specializing in genetic diseases and cancers has unveiled plans to present a series of findings at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, from…
Today, it was announced that new subgroup analyses from Ionis and AstraZeneca’s Phase 3 NEURO-TTRansform study of WAINUA™ (eplontersen) will be presented at the 2024 International Symposium on Amyloidosis (ISA)…
After intensive negotiations, WHO Member States have concluded discussions aimed at enhancing global readiness for future pandemics and outbreaks following the COVID-19 crisis. They have agreed to present the outcomes…